Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Panagiotis A. Konstantinopoulos, Su Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan T. Schumer, L. Austin Doyle, Elizabeth K. Lee, Elise C. Kohn, Linda R. Duska, Marta A. Crispens, Alexander B. Olawaiye, Ira S. Winer, Lisa M. Barroilhet, Siqing Fu, Michael T. McHale, Russell J. Schilder, Anniina Färkkilä, Dipanjan Chowdhury, Jennifer Curtis, Roxanne S. QuinnBrittany Bowes, Alan D. D'Andrea, Geoffrey I. Shapiro, Ursula A. Matulonis

Research output: Contribution to journal › Article › peer-review

135 Scopus citations

Fingerprint

Dive into the research topics of 'Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences